Medicare to Cover Wegovy and Zepbound at $50/Month Starting July 1

Medicare will cover select GLP-1 weight-loss medications for the first time starting July 1, 2026.

Medicare Opens the Door to Weight-Loss Medication Coverage

For the first time ever, Medicare beneficiaries will gain affordable access to FDA-approved weight-loss medications. The Centers for Medicare & Medicaid Services (CMS) announced the launch of the Medicare GLP-1 Bridge program starting July 1, 2026. This landmark demonstration program will allow eligible Part D enrollees to access selected metabolic treatments for a flat $50 monthly copay per 30-day supply.

The program is set to run through December 31, 2027. It represents a massive shift in healthcare policy, as Medicare has been legally prohibited from covering weight loss medications since 2003, according to the Kaiser Family Foundation (KFF).

Which Medications Are Covered

Under the new CMS guidelines, the Bridge program covers three specific medications designed to support metabolic health and weight loss:

• Wegovy (semaglutide) — Available in all formulations, including the subcutaneous injection and the oral tablet.
• Zepbound (tirzepatide) — Covered exclusively in the KwikPen formulation (single-dose vials and pens are excluded).
• Foundayo — Covered in all available formulations.

If you already receive a GLP-1 medication through Part D for type 2 diabetes, your coverage will continue under your current plan without changes. If you are exploring weight care for the first time, discussing semaglutide treatment programs or tirzepatide options with a provider is a great first step.

Who Qualifies for the Program

The GLP-1 Bridge program has specific medical and enrollment requirements to ensure the treatment reaches those who need it most. According to CMS, you must be enrolled in a Medicare Part D plan or a Medicare Advantage plan with drug coverage, and meet one of the following criteria:

• A BMI of 35 or greater, with no other underlying health conditions required.
• A BMI of 30 or greater combined with a diagnosis of heart failure, high blood pressure, or kidney disease.
• A BMI of 27 or greater alongside prediabetes, a history of heart attack or stroke, or peripheral artery disease.

Your doctor must submit a prescription and a prior authorization form to CMS to confirm your eligibility. The electronic system will open on July 1, 2026, with detailed clinical forms arriving in June.

Key Details and Limitations

According to KFF analysis, there are a few important limitations to keep in mind. Because this program is structured as a separate demonstration, your $50 copayments will not count toward your standard Part D deductible or your yearly out-of-pocket maximum. Additionally, manufacturer savings cards or copay coupons cannot be combined with this Medicare benefit.

Despite these limits, the program represents a life-changing opportunity for more than 67 million Medicare beneficiaries. The total number of participants will depend on how many meet the clinical requirements and complete the authorization process.

What Comes Next

Advocacy groups like the Obesity Action Coalition have praised the Bridge program for addressing an urgent gap in senior healthcare. While the more permanent BALANCE Model remains delayed, this program offers immediate relief for eligible seniors. Navigating insurance can be complex, so starting the discussion early is key.

If you want to find out if you qualify for these newly covered treatments, you can check if you qualify through our clinical assessment tools. A licensed provider can review your medical history and help you prepare the necessary Medicare paperwork.

This article is for informational purposes only and is not medical advice. Consult your healthcare provider before starting any weight loss medication or treatment.